Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Doxorubicin 5Cyclophosphamide 4Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2anlotinib 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1relmacabtagene autoleucel 1regorafenib 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1irinotecan sucrosofate 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Control Groups × Sarcoma × Clear all
NCT06772233 2025-07-31

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Peking University

Phase 2 Not yet recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡